Thomas Reiser/X
Aug 19, 2025, 14:02
Thomas Reiser Invites Clinicians to Join ISTH Survey on APS Diagnosis and Antithrombotic Treatment in Acute Ischemic Cardiac Disease
Thomas Reiser, Executive Director of International Society on Thrombosis and Haemostasis (ISTH), shared a post on X:
“Your expertise is requested!
Take this survey from the ISTH SSC Subcom. on Lupus Anticoagulant/Antiphospholipid Antibodies on APS diagnosis and antithrombotic treatment in patients with acute ischemic cardiac disease to assess current clinical practices.”
Check for more information here.
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis